



chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o  
If an  
emerging  
growth  
company,  
indicate by  
check mark if  
the registrant  
has elected  
not to use the  
extended  
transition  
period for  
complying  
with any new  
or revised  
financial  
accounting  
standards  
provided  
pursuant to  
Section 13(a)  
of the  
Exchange  
Act.

o

Item 2.02. Results of Operations and Financial Condition.

On January 7, 2019, Luminex Corporation ("the Company") issued a press release announcing preliminary revenue for the fourth quarter and full year 2018. A copy of the press release is furnished herewith as Exhibit 99.1

Item 7.01. Regulation FD Disclosure.

On January 9, 2019, the Company is giving a presentation ("Investor Presentation") to investors discussing, among other topics, an overview of the Company's business and growth strategy. The presentation will be at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA and will begin at 5:30 p.m. Pacific time (8:30 p.m. Eastern time). A copy of the Investor Presentation, which is available at [www.luminexcorp.com](http://www.luminexcorp.com), is being furnished as Exhibit 99.2 to this Form 8-K and is incorporated herein by reference.

The information in Item 2.02 and 7.01 of this Current Report on Form 8-K, including the Press Release attached as Exhibit 99.1 and Investor Presentation attached as Exhibit 99.2, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liabilities under that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Press Release issued by Luminex Corporation dated January 7, 2019.

99.2 Investor Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 7, 2019 LUMINEX CORPORATION

By: /s/ Harriss T. Currie

Name: Harriss T. Currie

Title: Chief Financial Officer, Senior Vice President of Finance